Canada Cell And Gene Therapy Manufacturing Market Size & Outlook
Global Market
Related Markets
Canada cell and gene therapy manufacturing market highlights
- The Canada cell and gene therapy manufacturing market generated a revenue of USD 344.5 million in 2022 and is expected to reach USD 2,400.4 million by 2030.
- The Canada market is expected to grow at a CAGR of 27.5% from 2023 to 2030.
- In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
- Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell and gene therapy manufacturing market data book summary
| Market revenue in 2022 | USD 344.5 million |
| Market revenue in 2030 | USD 2,400.4 million |
| Growth rate | 27.5% (CAGR from 2023 to 2030) |
| Largest segment | Cell therapy |
| Fastest growing segment | Gene Therapy |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy |
| Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, Canada accounted for 4.7% of the global cell and gene therapy manufacturing market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cell and gene therapy manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 2,400.4 million by 2030.
Canada has made a medical breakthrough in advanced therapy products. Glybera, the world's first approved gene therapy, was developed in Canada. However, the drug was taken back from the market and is being reviewed by the National Research Council of Canada.
With growing demand for cell and gene therapy products, the need for cell & gene therapy manufacturing in Canada, to accelerate implementation of innovative treatment concepts into standard clinical practices by operating under a common seal of quality, is also increasing.
CellCAN is a Canadian network for regenerative medicine and cell therapy, which focuses on improving the quality, safety, and feasibility of gene & cell therapies in Canada by optimizing manufacturing processes.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Cell And Gene Therapy Manufacturing Market Scope
Cell And Gene Therapy Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Hitachi Ltd | View profile | 322,525 | 6-6, Marunouchi 1-chome, Chiyoda-ku, Tokyo, Japan, 100-8280 | www.hitachi.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Takara Bio Inc | View profile | 1,793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | www.takara-bio.co.jp |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
Canada Cell And Gene Therapy Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Cell Therapy was the largest segment with a revenue share of 61.1% in 2022.
Horizon Databook has segmented the Canada cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Canada has made a medical breakthrough in advanced therapy products. Glybera, the world's first approved gene therapy, was developed in Canada. However, the drug was taken back from the market and is being reviewed by the National Research Council of Canada.
With growing demand for cell and gene therapy products, the need for cell & gene therapy manufacturing in Canada, to accelerate implementation of innovative treatment concepts into standard clinical practices by operating under a common seal of quality, is also increasing.
CellCAN is a Canadian network for regenerative medicine and cell therapy, which focuses on improving the quality, safety, and feasibility of gene & cell therapies in Canada by optimizing manufacturing processes.
- Canada Cell And Gene Therapy Manufacturing Market Therapy Type Outlook (Revenue, USD Million , 2018-2030)
- Gene Therapy
- Cell Therapy
- Canada Cell And Gene Therapy Manufacturing Market Scale Outlook (Revenue, USD Million , 2018-2030)
- Pre-commercial/ R&D Scale
- Commercial Scale
- Canada Cell And Gene Therapy Manufacturing Market Mode Outlook (Revenue, USD Million , 2018-2030)
- Contract manufacturing
- In house manufacturing
- Canada Cell And Gene Therapy Manufacturing Market Workflow Outlook (Revenue, USD Million , 2018-2030)
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical & Quality Testing
- Raw Material Testing
- Vector Production
- Others
- Canada Cell And Gene Therapy Manufacturing Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Malignancies
- Musculoskeletal therapies
- Autoimmune disorders
- Dermatology
- Large B-Cell Lymphoma
- Spinal Muscular Atrophy (SMA)
- Others
Reasons to subscribe to Cell And Gene Therapy Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy Manufacturing Market Outlook databook
- Our clientele includes a mix of Cell And Gene Therapy Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Cell And Gene Therapy Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Cell And Gene Therapy Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Canada Cell And Gene Therapy Manufacturing Market, 2018-2030 (US$M)
Canada cell and gene therapy manufacturing market statistics, by therapy type, 2018-2030 (US$M)
